Aerogen Pharma is developing AeroFact™, a non-invasive aerosolized pulmonary surfactant therapy for respiratory distress syndrome (RDS) in preterm infants. This investigational treatment uses proprietary vibrating mesh technology to deliver ultra-fine aerosolized surfactant, aiming to reduce complications and maintain continuous ventilation support.
Funding
Funding not disclosed
Founders
Product
Problem
The current standard of care for respiratory distress syndrome (RDS) in preterm infants involves invasive surfactant administration, which carries risks of complications and patient discomfort. This method also necessitates interruption of non-invasive ventilation support during administration.
Solution
Aerogen Pharma is developing AeroFact™, an investigational, non-invasive aerosolized pulmonary surfactant therapy designed to treat RDS in preterm infants. This approach aims to reduce the complications associated with invasive surfactant delivery and minimize patient discomfort. By delivering surfactant via aerosol, the therapy seeks to avoid the need for intubation and maintain continuous non-invasive ventilation support. This novel method targets efficient lung deposition, potentially improving outcomes for critically ill neonates.
Target Audience
The primary target audience includes neonatologists, pediatric pulmonologists, and healthcare systems focused on neonatal critical care.
Features
- Investigational AeroFact™ program utilizing a non-invasive aerosolized pulmonary surfactant treatment for Respiratory Distress Syndrome (RDS).
- Proprietary Photo-Defined Aperture Plate (PDAP) technology, a vibrating mesh system with up to 24,000 precision-formed apertures designed for independent specification of droplet size and liquid output rate.
- Capability to aerosolize challenging formulations, such as undiluted pulmonary surfactant with high viscosity and low surface tension.
- Generation of an ultra-fine, ultra-respirable aerosol plume with a small droplet size and increased respirable fraction.
- Potential for rapid aerosol generation within milliseconds, synchronized with inspiration for efficient lung deposition.
- Designed for compatibility with a broad range of invasive and non-invasive ventilatory modes and parameters, including nCPAP.
- Aims to facilitate breath-actuated drug delivery through a combination of a custom vibrating mesh nebulizer, respiration sensor, and reusable controller.
- Modular device design intended for use with multiple Aerogen Pharma drug products, co-packaged with appropriate nebulizers and interfaces.